Other languages Neurogene Inc.

Equities

NGNE

US64135M1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
32.9 ^USD	-3.06%		-2.58%	+69.76%

May. 07	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	CI
Apr. 29	Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	May. 07
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	Mar. 04
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	Feb. 21
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer	Jan. 17
Neurogene Names Julie Jordan as Chief Medical Officer	Jan. 16
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	Jan. 16
Neurogene Announces Business Update and 2024 Outlook	Jan. 05
Neurogene Completes Merger With Neoleukin Therapeutics	Dec. 19
Neurogene Inc. completed the acquisition of Neoleukin Therapeutics, Inc. from a group of shareholders for approximately $120 million in a reverse merger transaction.	Dec. 17
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Sector Update: Health Care Stocks Rise Slightly Late Afternoon	23-09-22
Sector Update: Health Care Stocks Mixed Friday Afternoon	23-09-22
Neoleukin Therapeutics Board Approves 1-for-5 Reverse Stock Split	23-09-22
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Neoleukin Therapeutics to Merge With Neurogene in All-Stock Deal	23-07-18
Neoleukin Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08
Neoleukin Therapeutics, Inc. Appoints Donna M. Cochener as the Interim Chief Executive Officer	23-04-03
Neoleukin Therapeutics, Inc. Announces Board Changes	23-03-10
Sector Update: Healthcare Stocks Stumble Late	23-03-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Neurogene Inc.

Equities

NGNE

US64135M1053

Other languages

Filters